Table 2.
Comparison of Patients’ Characteristics between CVR and PVR at 2 Years after ETV Commencement
| Characteristics | CVR (n=324) | PVR (n=35) | p-value |
|---|---|---|---|
| Age, yr | 53±9 | 54±11 | 0.424 |
| Male sex | 203 (62.7) | 28 (80.0) | 0.042 |
| AST, IU/L | 33±13 | 40±21 | 0.051 |
| ALT, IU/L | 30±16 | 35±20 | 0.161 |
| Total bilirubin, mg/dL | 1.3±1.0 | 1.3±0.7 | 0.687 |
| Albumin, g/dL | 4.1±0.5 | 3.9±0.6 | 0.024 |
| INR | 1.1±0.6 | 1.1±0.2 | 0.904 |
| Platelet count, ×103/μL | 107±45 | 104±40 | 0.731 |
| HBV DNA, log10 copies/mL | Undetectable | 2.7±1.0 | |
| Basal HBV DNA | 6.9±1.2 | 7.6±1.2 | 0.001 |
| HBeAg positivity | 107/305 (35.1) | 20/34 (58.9) | 0.002 |
| CP class | 0.072 | ||
| A | 294 (90.7) | 28 (80.0) | |
| B | 27 (8.3) | 7 (20.0) | |
| C | 3 (1.0) | 0 | |
| MELD score | 6.3±4.3 | 5.6±3.5 | 0.412 |
| APRI | 1.5±1.5 | 1.6±1.1 | 0.563 |
| FIB-4 index | 3.8±2.7 | 4.5±3.1 | 0.129 |
Data are presented as mean±SD or number (%).
CVR, complete virological response; PVR, partial virological response; ETV, entecavir; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; CP, Child-Pugh; MELD, Model for End-Stage Liver Disease; APRI, aspartate transaminase to platelet ratio index.